Literature DB >> 20400477

BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.

Peter J O'Donovan1, David M Livingston.   

Abstract

BRCA1 and BRCA2 are tumor suppressor genes, familial mutations in which account for approximately 5% of breast cancer cases in the USA annually. Germ line mutations in BRCA1 that truncate or inactivate the protein lead to a cumulative risk of breast cancer, by age 70, of up to 80%, whereas the risk of ovarian cancer is 30-40%. For germ line BRCA2 mutations, the breast cancer cumulative risk approaches 50%, whereas for ovarian cancers, it is between 10 and 15%. Both BRCA1 and BRCA2 are involved in maintaining genome integrity at least in part by engaging in DNA repair, cell cycle checkpoint control and even the regulation of key mitotic or cell division steps. Unsurprisingly, the complete loss of function of either protein leads to a dramatic increase in genomic instability. How they function in maintaining genome integrity after the onset of DNA damage will be the focus of this review.

Entities:  

Mesh:

Year:  2010        PMID: 20400477     DOI: 10.1093/carcin/bgq069

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  111 in total

1.  The C-terminal proteolytic fragment of the breast cancer susceptibility type 1 protein (BRCA1) is degraded by the N-end rule pathway.

Authors:  Zhizhong Xu; Roshani Payoe; Richard P Fahlman
Journal:  J Biol Chem       Date:  2012-01-18       Impact factor: 5.157

2.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Authors:  Kelly L Bolton; Georgia Chenevix-Trench; Cindy Goh; Siegal Sadetzki; Susan J Ramus; Beth Y Karlan; Diether Lambrechts; Evelyn Despierre; Daniel Barrowdale; Lesley McGuffog; Sue Healey; Douglas F Easton; Olga Sinilnikova; Javier Benítez; María J García; Susan Neuhausen; Mitchell H Gail; Patricia Hartge; Susan Peock; Debra Frost; D Gareth Evans; Rosalind Eeles; Andrew K Godwin; Mary B Daly; Ava Kwong; Edmond S K Ma; Conxi Lázaro; Ignacio Blanco; Marco Montagna; Emma D'Andrea; Maria Ornella Nicoletto; Sharon E Johnatty; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Ellen L Goode; Brooke L Fridley; Jennifer T Loud; Mark H Greene; Phuong L Mai; Angela Chetrit; Flora Lubin; Galit Hirsh-Yechezkel; Gord Glendon; Irene L Andrulis; Amanda E Toland; Leigha Senter; Martin E Gore; Charlie Gourley; Caroline O Michie; Honglin Song; Jonathan Tyrer; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Ulf Kristoffersson; Håkan Olsson; Åke Borg; Douglas A Levine; Linda Steele; Mary S Beattie; Salina Chan; Robert L Nussbaum; Kirsten B Moysich; Jenny Gross; Ilana Cass; Christine Walsh; Andrew J Li; Ronald Leuchter; Ora Gordon; Montserrat Garcia-Closas; Simon A Gayther; Stephen J Chanock; Antonis C Antoniou; Paul D P Pharoah
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

3.  Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.

Authors:  Joyce Liu; Mihaela C Cristea; Paul Frankel; Susan L Neuhausen; Linda Steele; Verena Engelstaedter; Ursula Matulonis; Sharon Sand; Nadine Tung; Judy E Garber; Jeffrey N Weitzel
Journal:  Cancer Genet       Date:  2012 Jan-Feb

Review 4.  Autophagy regulation in the development and treatment of breast cancer.

Authors:  Yuting Zhou; Edmund B Rucker; Binhua P Zhou
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-12-05       Impact factor: 3.848

Review 5.  Autophagy and cancer cell metabolism.

Authors:  Fred Lozy; Vassiliki Karantza
Journal:  Semin Cell Dev Biol       Date:  2012-01-18       Impact factor: 7.727

6.  The Potential Predictors in Chemotherapy Sensitivity.

Authors:  Eun-Kyu Kim; Hee-Chul Shin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?

Authors:  Rachel Mitchell; Lela Buckingham; Melody Cobleigh; Jacob Rotmensch; Kelly Burgess; Lydia Usha
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

Review 8.  The Werner's Syndrome RecQ helicase/exonuclease at the nexus of cancer and aging.

Authors:  Stephen G Chun; David S Shaeffer; Peter K Bryant-Greenwood
Journal:  Hawaii Med J       Date:  2011-03

Review 9.  Emergence of Circulating MicroRNAs in Breast Cancer as Diagnostic and Therapeutic Efficacy Biomarkers.

Authors:  Vaishali Aggarwal; Kumari Priyanka; Hardeep Singh Tuli
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

10.  BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1.

Authors:  Jianqiu Zou; Deli Zhang; Guang Qin; Xiangming Chen; Hongmin Wang; Dong Zhang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.